EP Patent

EP4099987B1 — Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Assigned to Adverio Pharma GmbH · Expires 2025-03-12 · 1y expired

What this patent protects

Patent listed against Verquvo.

Drugs covered by this patent

Patent Metadata

Patent number
EP4099987B1
Jurisdiction
EP
Classification
—
Expires
2025-03-12
Drug substance claim
No
Drug product claim
No
Assignee
Adverio Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.